证券代码：603207 证券简称：小方制药 公告编号：2025-043 上海小方制药股份有限公司 2025年第二次临时股东大会决议公告 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 10 日 (二)股东会召开的地点：上海市浦东新区东方路 877 号嘉兴大厦 17 楼 | 1、出席会议的股东和代理人人数 | 143 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 106,235,900 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 66.1658 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东大会由公司董事会召集，董事长方之光先生主持，采用现场投票与网 络投票相结合的表决方式。本次股东大会的召集、召开及表决程序符 ...

к⎧ᐲ⸣䰘а䐟 ਧ ޤъཚਔ≷俉ޤъѝᗳаᓗ ቲ 䛞㕆˖ ⭥䈍˖ Րⵏ˖ ޣҾк⎧ሿᯩࡦ㦟㛑ԭᴹ䲀ޜਨ ᒤㅜҼ⅑Ѥᰦ㛑ьབྷՊѻ⌅ᖻ㿱Җ ൘ࠪާᵜ⌅ᖻ㿱Җѻࡽˈᵜᡰᖻᐸ༠᰾ྲл˖ NJ⌅࣎⨶㇑࣑ᖻъ⌅ࡨᡰӾһ䇱࣑NJljᖻᐸһ⌅ࡨᦞlj䇱ᵜᡰ৺ᵜᡰᖻᐸ ઼ljᖻᐸһ࣑ᡰ䇱ࡨ⌅ᖻъ࣑ᢗъ㿴ࡉ˄䈅㹼˅NJㅹ㿴ᇊ৺ᵜ⌅ᖻ㿱Җࠪާᰕԕ 㠤˖к⎧ሿᯩࡦ㦟㛑ԭᴹ䲀ޜਨ ੋਸᖻᐸһ࣑ᡰк⎧࠶ᡰ˄ԕлㆰ〠Āᵜᡰā˅᧕ਇк⎧ሿᯩࡦ㦟㛑ԭᴹ䲀ޜ ਨ˄ԕлㆰ〠Āޜਨā˅ⲴငᢈˈṩᦞljѝॾӪ≁ޡ઼ഭޜਨ⌅NJ˄ԕлㆰ〠Āljޜ ਨ⌅NJā˅ǃljѝॾӪ≁ޡ઼ഭ䇱ࡨ⌅NJ˄ԕлㆰ〠Ālj䇱ࡨ⌅NJā˅ǃljкᐲޜਨ㛑ьՊ 㿴ࡉNJ˄ԕлㆰ〠Ālj㛑ьՊ㿴ࡉNJā˅ㅹ⌅ᖻǃ⌅㿴ǃ㿴㤳ᙗ᮷Ԧ˄ԕлㆰ〠³⌅ᖻǃ ⌅㿴´˅৺ljк⎧ሿᯩࡦ㦟㛑ԭᴹ䲀ޜਨㄐ〻NJ˄ԕлㆰ〠Āljޜਨㄐ〻NJā˅Ⲵᴹޣ 㿴ᇊˈ᤹➗ᖻᐸ㹼ъޜ䇔Ⲵъ࣑ḷ߶ǃ䚃ᗧ㿴㤳઼औࣹቭ䍓㋮⾎ˈቡޜਨ ᒤ ㅜҼ⅑Ѥᰦ㛑ьབྷՊ˄ԕлㆰ〠Āᵜ⅑㛑ьབྷՊā˅ᴹޣһᇌࠪާᵜ⌅ᖻ㿱ҖDŽ Ѫࠪާᵜ⌅ᖻ㿱ҖѻⴞⲴˈᵜᡰင⍮ᖻᐸ˄ԕлㆰ〠Āᵜᡰᖻᐸā˅ሩޜਨ ᨀⲴоᵜ⅑㛑ьབྷՊᴹޣⲴ᮷Ԧ ...

Group 1 - The company announced that on November 10, 2025, the board received a written resignation from Zhang Changwei, who resigned from his position as a non-independent director due to work adjustments, while continuing to serve as the factory manager [1] - On the same day, the company held a staff representative meeting to elect Yin Yufeng as the employee representative director of the second board, with a term lasting until the end of the second board's term [1] - Zhang Changwei does not hold any direct shares in the company and will comply with relevant commitments after his resignation [1] Group 2 - Yin Yufeng has previously held positions within the company, including assistant manager and manager of the marketing department, as well as supervisor [1]

Core Viewpoint - The company reported that as of October 31, 2025, the number of shareholders will be 13,364 [1] Summary by Categories - Company Information - The company, Xiaofang Pharmaceutical (stock code: 603207), has communicated with investors regarding its shareholder count [1] - Shareholder Data - The projected number of shareholders by the end of October 2025 is 13,364 [1]

上海小方制药股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 11 月 证券代码：603207 证券简称：小方制药 上海小方制药股份有限公司 2025 年第二次临时股东大会资料目录 | 2025 | 年第二次临时股东大会会议须知 | 3 | | --- | --- | --- | | 2025 | 年第二次临时股东大会会议议程 | 5 | | 2025 | 年第二次临时股东大会会议议案一 | 7 | | 2025 | 年第二次临时股东大会会议议案二 | 9 | | 2025 | 年第二次临时股东大会会议议案三 | 10 | 2 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保上海小方制药股份有限公司（以下简称"公 司"）股东大会的正常秩序和议事效率，保证大会的顺利进行，根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司股东会规则》以及《上海小方 制药股份有限公司章程》（以下简称"《公司章程》"）《上海小方制药股份有限 公司股东大会议事规则》等相关规定，特制定本须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人 员将对出席会议者的 ...

Core Insights - Xiaofang Pharmaceutical, established in August 1993, is a well-known domestic external medicine company that focuses on R&D, production, and sales of external medicines, with certain technological barriers and brand advantages. The company is set to be listed on the Shanghai Stock Exchange on August 26, 2024 [1]. Financial Performance - For Q3 2025, Xiaofang Pharmaceutical reported a revenue of 397 million yuan, ranking 85th among 110 companies in the industry. The top company, Huadong Medicine, had a revenue of 32.664 billion yuan, while the industry average was 2.8 billion yuan [2]. - The net profit for the same period was 170 million yuan, placing the company 37th in the industry. The leading company, Hengrui Medicine, reported a net profit of 5.76 billion yuan, with the industry average at 299 million yuan [2]. Financial Ratios - As of Q3 2025, Xiaofang Pharmaceutical's debt-to-asset ratio was 19.39%, up from 11.91% the previous year, which is significantly lower than the industry average of 35.26%, indicating strong solvency [3]. - The gross profit margin for Q3 2025 was 66.74%, slightly up from 65.86% year-on-year, which is higher than the industry average of 57.17%, reflecting strong profitability [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.02% to 13,400, with an average holding of 4,073.08 circulating A-shares, which is an increase of 1.03% [5]. - Among the top ten circulating shareholders, Guangfa Multi-Dimensional Emerging Stock (003745) entered the list with 753,100 shares, while several funds exited the top ten [5]. Management Compensation - The chairman and general manager, Fang Zhiguang, received a salary of 1.2274 million yuan in 2024, unchanged from 2023 [4].

Group 1 - The core point of the article is that Xiaofang Pharmaceutical (603207.SH) reported its Q3 2025 results, highlighting significant institutional ownership and changes in public fund disclosures [1] - As of October 24, 2025, a total of 9 institutional investors hold shares in Xiaofang Pharmaceutical, amounting to 113 million shares, which represents 70.24% of the total share capital [1] - The institutional ownership decreased by 1.14 percentage points compared to the previous quarter [1] Group 2 - One new public fund was disclosed this period, namely the GF Multi-Dimensional Emerging Stock Fund [1] - A total of 121 public funds were not disclosed this period compared to the previous quarter, including several notable funds such as CITIC Securities Rotation Mixed A and CITIC Securities Selected Mixed A [1] Group 3 - In terms of foreign investment, one new foreign institution was disclosed, which is Yunjia Far East Co., Ltd [2] - The same foreign institution, Yunjia Far East Co., Ltd, was not disclosed in the previous quarter [2]

Core Viewpoint - Xiaofang Pharmaceutical (603207.SH) reported a year-on-year revenue increase of 8.17% for the first three quarters of 2025, reaching 397 million yuan, along with a net profit attributable to shareholders of 170 million yuan, reflecting a growth of 5.09% [1] Financial Performance - Total operating revenue for the first three quarters of 2025 was 397 million yuan, representing an 8.17% increase year-on-year [1] - Net profit attributable to the parent company's shareholders was 170 million yuan, showing a year-on-year growth of 5.09% [1] - Basic earnings per share stood at 1.06 yuan [1]

Group 1 - The core point of the article is that Xiaofang Pharmaceutical announced a board meeting to discuss the replacement of the auditing firm for the fiscal year 2025 [1] - For the fiscal year 2024, Xiaofang Pharmaceutical's revenue composition is 99.93% from pharmaceutical preparations and 0.07% from other businesses [1] - As of the report date, Xiaofang Pharmaceutical has a market capitalization of 5.2 billion yuan [1] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year [1] - It discusses the current hot secondary market for biomedicine while noting that the primary market is facing challenges in fundraising [1]

上海小方制药股份有限公司 章 程 二○二五年十月 | 第一章 | 总则 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 服份 | | 第一节 | 股份发行 . | | 第二节 | 股份增减和回购 | | 第三节 股份转让 . | | | 第四章 股东和股东会 | | | 第一节 | 股东的一般规定 | | 第二节 | 控股股东和实际控制人 . | | 第三节 | 股东会的一般规定 . | | 第四节 | 股东会的召集 . | | 第五节 | 股东会的提案与通知 | | 第六节 | 股东会的召开 . | | 第七节 股东会的表决和决议 | | | 第五章 | 董事会 | | 第一节 | 董事的一般规定 . | | 第二节 | 重事公 …………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 27 | | 第三节 | 独立董事 | | 第四节 | 董事会专门委员会 . | | 第六章 | 高级管理人员 . | | 第七章 | ...